We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Plasma Human Proteins Associated with Acute Pediatric Malaria

By LabMedica International staff writers
Posted on 27 Nov 2018
Print article
Image: The FLEXMAP 3D instrument is an advanced and versatile multiplexing platform. The platform uses both magnetic and non-magnetic microspheres and is capable of simultaneously measuring up to 500 genes or proteins from a small sample (Photo courtesy of Luminex).
Image: The FLEXMAP 3D instrument is an advanced and versatile multiplexing platform. The platform uses both magnetic and non-magnetic microspheres and is capable of simultaneously measuring up to 500 genes or proteins from a small sample (Photo courtesy of Luminex).
Severe malaria caused by Plasmodium falciparum continues to be one of the leading infectious causes of morbidity and mortality in children worldwide. The intimate interaction between the pathophysiology of the human host and the biology of the P. falciparum parasite results in a wide spectrum of disease outcomes in malaria.

Development of severe disease is associated with a progressively augmented imbalance in pro- and anti-inflammatory responses to high parasite loads and sequestration of parasitized erythrocytes. Although these phenomena collectively constitute common denominators for the wide variety of discrete severe malaria manifestations, the mechanistic rationales behind discrepancies in outcome are poorly understood.

Protein scientists from the KTH Royal Institute of Technology (Stockholm, Sweden) and their colleagues collected plasma samples from pediatric malaria patients, as well as community controls, in the regional hospital as well as health centers in a catchment area of Rwanda. The patients were enrolled over a 3-year period, that begun in 2011 and ended in 2014. In total, 541 samples were analyzed with associated clinical data, including 178 controls, 183 patients with mild malaria and 180 patients with severe malaria. The team screened a total of 255 antibodies, targeting 115 unique human proteins, as well as assay specific controls and analyzed on a Flexmap 3D instrument.

The team identified 57 proteins with significantly altered levels in patients with malaria compared to controls. From these, the 27 most significant proteins were selected for a stringent analysis approach. There were 24 proteins that showed elevated levels in malaria patients and included proteins involved in acute inflammatory response as well as cell adhesion. The remaining three proteins, also implicated in immune regulation and cellular adhesivity, displayed lower abundance in malaria patients. In addition, 37 proteins were identified with increased levels in patients with severe compared to mild malaria. This set includes, proteins involved in tissue remodeling and erythrocyte membrane proteins. Collectively, this approach has been successfully used to identify proteins both with known and unknown association with different stages of malaria.

The authors concluded that a set of promising candidate markers have been identified that significantly separate mild and severe malaria cases, despite the clinical overlap between these disease states. New potential markers were identified that could be important leads towards an increased understanding of host-parasite interaction and pathogenesis of the disease. The study was published on November 15, 2018, in the Malaria Journal.

Related Links:
KTH Royal Institute of Technology

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.